Dr. Sotomayor on Differences Between FDA-Approved CAR T-Cell Therapies

Video

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

There are 2 FDA-approved CD19-directed CAR T-cell therapies: axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah). Both products are approved for the treatment of relapsed/refractory non-Hodgkin lymphoma, but tisagenlecleucel is also approved for pediatric patients with acute lymphoblastic leukemia. Although both products target CD19, they have different co-stimulatory domains, explains Sotomayor. CD28 is the costimulatory domain for axi-cel, whereas 4-1BB is the costimulatory domain for tisagenlecleucel. CAR T cells that rely on CD28 are more potent but have a shorter half-life, adds Sotomayor. Conversely, 4-1BB is less potent but has greater CAR T-cell persistence.

Now, researchers are investigating ways to extend the persistence of CD28 costimulatory products without decreasing efficacy. Research is also being dedicated to minimizing the toxicities associated with these products by modulating inflammatory cytokines, says Sotomayor. This approach may reduce the incidence of cytokine release syndrome and neurotoxicity.

Recent Videos
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Brian Kim, MBA, the chief executive officer of Mission Bio
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Ben Samelson-Jones, MD, PhD, an assistant professor of pediatric hematology at Perelman School of Medicine, University of Pennsylvania, and the associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Roger Hajjar, MD, the director of the GCTI
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy Development
© 2025 MJH Life Sciences

All rights reserved.